Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.83 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.83 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.83 |
| ▸ | PREP | P48147 | 2/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4415016 | 1.00 | DPP4 (0.83) | DPP4DPP8DPP7PREPADRB2 | |
| SCHEMBL4415004 | 0.90 | DPP4 (0.69) | DPP4DPP8DPP7PREP | |
| SCHEMBL4415011 | 0.90 | DPP4 (0.69) | DPP4DPP8DPP7PREP | |
| SCHEMBL4409975 | 0.89 | DPP4 (0.68) | DPP4DPP8DPP7PREP | |
| SCHEMBL4409971 | 0.89 | DPP4 (0.68) | DPP4DPP8DPP7PREP | |
| SCHEMBL4412868 | 0.88 | DPP4 (0.73) | DPP4DPP8DPP7 | |
| SCHEMBL4412869 | 0.88 | DPP4 (0.73) | DPP4DPP8DPP7 | |
| SCHEMBL4411623 | 0.88 | DPP4 (0.67) | DPP4DPP8DPP7PREP | |
| SCHEMBL4411627 | 0.88 | DPP4 (0.67) | DPP4DPP8DPP7PREP | |
| SCHEMBL4414148 | 0.85 | DPP4 (0.75) | DPP4DPP8DPP7PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2009-12-29 | — | — | US | claimed |
| EP-1625122-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| US-20040254226-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-16 | — | — | US | claimed |
| WO-2004103993-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-12-02 | — | — | WO | claimed |
| US-7638638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| EP-1625122-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20040254226-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004103993-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254226-A1 | Dipeptidyl peptidase inhibitors | DPP3, DPP4, DPP7 | DPP4 2/4885DPP8 5/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.